

dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease.

[Download Here](#)

NCBI Resources How To



US National Library of Medicine
National Institutes of Health

PMC

[Advanced](#) [Journal list](#)

[Journal List](#) › [HHS Author Manuscripts](#) › [PMC4312512](#)



HHS Public Access
Author manuscript
Peer-reviewed and accepted for publication

[About author manuscripts](#) [Submit a manuscript](#)

Formats:

[Article](#) | [PubMed](#)
(638K) | [Citation](#)

Share

 Facebook

[Circ Res.](#) Author manuscript; available in PMC 2016 Jan 30.

PMCID: PMC4312512

NIHMSID: NIHMS641127

Published in final edited form as:

PMID: [25599331](#)

[Circ Res.](#) 2015 Jan 30; 116(3): 448–455.

Published online 2014 Nov 5.

doi: [10.1161/CIRCRESAHA.116.305360](#)

Gut Microbiota-Dependent Trimethylamine N-oxide (TMAO) Pathway Contributes to Both Development of Renal Insufficiency and Mortality Risk in Chronic Kidney Disease

[W. H. Wilson Tang](#),^{1,2} [Zeneng Wang](#),¹ [David J. Kennedy](#),¹ [Yuping Wu](#),³
[Jennifer A. Buffa](#),¹ [Brendan Agatisa-Boyle](#),¹ [Xinmin S. Li](#),¹ [Bruce S. Levison](#),¹ and
[Stanley L. Hazen](#)^{1,2}

[Author information](#) ► [Copyright and License information](#) ► [Disclaimer](#)

The publisher's final edited version of this article is available free at [Circ Res](#).
See commentary "[TMAO is both a Biomarker and a Renal Toxin](#)" in *Circ Res*,
volume 116 on page 396.

See other articles in PMC that [cite](#) the published article.

[Abstract](#)

Go to:

Author Manuscript

Author M

Rationale

[Go to:](#)

Trimethylamine-*N*-oxide (TMAO), a gut microbial-dependent metabolite of dietary choline, phosphatidylcholine (lecithin) and L-carnitine, is elevated in chronic kidney diseases (CKD) and associated with coronary artery disease pathogenesis.

Objective

[Go to:](#)

To both investigate the clinical prognostic value of TMAO in subjects with versus without CKD, and to test the hypothesis that TMAO plays a direct contributory role in the development and progression of renal dysfunction.

Methods and Results

[Go to:](#)

We first examined the relationship between fasting plasma TMAO and all-cause mortality over 5-year follow-up in 521 stable subjects with CKD (estimated glomerular filtration rate [eGFR] <60 ml/min/1.73m²). Median TMAO level among CKD subjects was 7.9 μM (interquartile range 5.2–12.4μM), which was markedly higher (P<0.001) than in non-CKD subjects (n=3,166). Within CKD subjects, higher (4th vs. 1st quartile) plasma TMAO level was associated with a 2.8-fold increased mortality risk. Following adjustments for traditional risk factors, hsCRP and eGFR, elevated TMAO levels remained predictive of 5-year mortality risk (HR 1.93 [95%CI 1.13–3.29], p<0.05). TMAO provided significant incremental prognostic value (net reclassification index 17.26%, p<0.001; and differences in area under Receiver Operator Characteristic curve, 63.26% vs. 65.95%, p=0.036). Among non-CKD subjects, elevated TMAO levels portend poorer prognosis within cohorts of high and low cystatin C. In animal models, elevated dietary choline or TMAO directly led to progressive renal tubulointerstitial fibrosis and dysfunction.

Conclusion

[Go to:](#)

Plasma TMAO levels are both elevated in patients with CKD and portend poorer long-term survival. Chronic dietary exposures that increase TMAO appear to directly contribute to progressive renal fibrosis and dysfunction.

Keywords: Trimethylamine *N*-oxide, renal insufficiency, fibrosis, cardiovascular disease, gut microbiota

INTRODUCTION

Go to: 

Patients with chronic kidney disease (CKD) are at increased risk for development of cardiovascular disease (CVD) beyond traditional risk factors. Yet the mechanism(s) through which CKD is linked to enhanced atherosclerotic heart disease is not fully elucidated. While a role for uremic toxins in the pathogenesis of cardiovascular and renal disease progression in CKD has been suggested for some time, the precise participants involved, and their mechanisms of action remain unclear. Recent studies have suggested involvement of gut microbiota in the generation of metabolites that display uremic toxicity¹. Further, perturbations of the composition of the gut microbial community in both human and experimental CKD are associated with significant elevations of gut-derived uremic toxins². Such alterations have also been associated with increased systemic inflammatory burden, and thus are suspected to potentially play a role in the pathogenesis of cardiovascular and renal disease progression in subjects with CKD. Bacterial structural components such as lipopolysaccharide³, and metabolites such as indoxyl sulfate, p-cresyl sulfate, amines, and ammonia, have been identified as potential microbial byproducts capable of initiating pro-inflammatory cytokine/chemokine cascades seen in the setting of CKD and end stage renal disease⁴. Thus, it has been hypothesized that gut-microbiota derived uremic toxins may serve as both therapeutic targets and/or assessment tools for renal diseases in this vulnerable population^{1, 5-7}. However, demonstration of a role for these uremic toxins in CVD pathogenesis has been indirect.

Our group recently identified a novel mechanistic link between gut microbiota metabolism of dietary trimethylamine-containing nutrients, and CVD pathogenesis⁸⁻¹³. Specifically, gut microbiota-mediated metabolism of phosphatidylcholine, choline or *L*-carnitine each have been shown to ultimately produced trimethylamine-*N*-oxide (TMAO), and in multiple clinical studies, TMAO levels have been shown to be associated with cardiovascular risks^{8-10, 13}.

Further, animal model studies have revealed TMAO is mechanistically linked to atherosclerosis development through

multiple distinct pathways^{8, 14}. Animal model and human clinical studies demonstrate an obligatory role for gut microbiota in TMAO formation from TMA-containing nutrients including choline and phosphatidylcholine^{9, 10}, *L*-carnitine⁸, and more recently, γ -butyrobetaine¹⁵, and to a lesser degree, the choline oxidation metabolite betaine¹¹.

TMAO is cleared by the kidney, and prior studies have reported TMAO is elevated in subjects with impaired renal function^{16–18}. It is thus an attractive hypothesis that TMAO may represent an excellent mechanism-based marker of CVD risk in subjects with impaired renal function. In one large study of subjects with predominantly preserved renal function, we reported the prognostic value of TMAO for predicting three year risk for major adverse cardiovascular events (MACE = myocardial infarction, stroke or death) remained significant following adjustments for renal function⁹. However, no studies to date have directly looked at the long-term mortality risk of TMAO among CKD subjects. Interestingly, plasma TMAO levels in apparently healthy donors was identified in a prospective multicenter study aimed at identifying donor factors associated with delayed graft function in renal transplant recipients¹⁹. A direct role for TMAO in impacting renal functional impairment has not been reported. Herein, we sought to further examine both the prognostic value of TMAO among CKD subjects and the potential contribution of dietary-induced, gut microbiota-associated TMAO formation in the development and progression of CKD.

METHODS

Go to:

Human studies

This is a single-center, prospective cohort study approved by the Cleveland Clinic Institutional Review Board. We included adult subjects (ages 18 years and above) who underwent elective diagnostic coronary angiography for cardiac evaluation at our institution from 2001–2007 as previously described⁹. We excluded subjects with known acute coronary syndromes or revascularization procedures within 30 days of enrollment, or history of congenital heart disease. After informed consent, fasting plasma blood samples

Author Manuscript

were collected using ethylenediaminetetraacetic acid tubes prior to any drug administration via the arterial sheath, and immediately processed and frozen in -80°C until analysis. Estimated glomerular filtration rate (eGFR) was calculated according to the CKD-EPI creatinine and cystatin C formula²⁰, with CKD defined as eGFR <60 ml/min/1.73m² (CKD stage 3 or beyond). Ascertainment of all-cause mortality at 5-years was performed by prospective telephone contact and chart review plus interrogation of the Social Security Death Index (up to 2011).

Plasma analysis

Trimethylamine-N-oxide (TMAO) levels were determined by stable isotope dilution high-performance liquid chromatography with online electrospray ionization tandem mass spectrometry (LC/MS/MS) on an AB SCIEX 5500 triple quadrupole mass spectrometer (AB SCIEX, Framingham MA) using d₉-(trimethyl)-labeled internal standards as previously described^{10, 21}. High-sensitivity C-reactive protein (hsCRP), fasting lipid panel, cystatin C, and serum creatinine were measured using the Architect ci8200 platform (Abbott Laboratories, Abbott Park, IL).

Animal study

Author Manuscript

To directly test for a potential contribution of dietary choline or TMAO to promotion of renal dysfunction, C57BL6J mice were fed with the following diets for 6 weeks: i) a chemically defined diet comparable in composition to standard chow diet (Teklad 2018, Harland Laboratories) that contains 0.08% (gm/gm) total choline; ii) the same diet supplemented with choline (1.0% total); and iii) the same diet supplemented with TMAO (0.12%). A separate study included C57BL6J mice with ApoE^{-/-} background were fed with the same diet groups for comparing their cystatin C levels at 14 weeks of follow-up using a commercially available mouse enzyme-linked immunosorbent assay (R&D systems, Minneapolis MN). This study has been approved by the Cleveland Clinic Institutional Animal Care and Use Committee.

Quantitative histologic techniques

Mason's trichome staining was performed on deparafinized 5 μm

Author

serial kidney sections. The kidney sections were mounted under a Leica DM 2500 microscope and digitized with a QImaging MicroPublisher 5.0 RTV camera for wide field microscopy. Quantitative morphometric analysis was performed on cortical fields (at least 8 from each animal) lacking major blood vessels and the collagen volume was determined using automated (for batch analysis) and customized algorithms/scripts (ImageIQ Inc., Cleveland, OH) written for Image Pro Plus 7.0. Briefly, a set of representative images are chosen that demonstrated a wide range of staining intensities and prevalence. In an automated script, these “training” images were loaded one after another prompting the user to delineate “blue” pixels representing positive collagen staining using an interactive color picking tool. An iterative color profile or classifier was generated and subsequently applied to all images in a given directory using a fully automated algorithm. Positive pixels, as defined by the color profile, were segmented and summed to provide positive staining area. Total tissue area was determined by extracting the “saturation” channel, applying a lo-pass filter, and thresholding the result. Any area within the general tissue boundary that was empty (i.e. white) was removed by converting the original image to grayscale and applying a fixed threshold for non background pixels on adequately white-balanced images. Finally, total tissue area and total stained area were exported to Excel. For post-processing verification, segmented regions were superimposed onto the original image (green outlines) and saved for each image analyzed.

Preparation of tissue homogenates and immunoblotting

Equal amounts of protein were prepared using standard biochemical methods and subjected to SDS-PAGE and electrotransfer of proteins from gels to Immobilon-P membranes (Millipore). Membranes were incubated with the following antibodies: SMAD3 and phospho-SMAD-3(Ser^{423/425}) (Cell Signaling Technology); tubulin (Santa Cruz Biotechnology); KIM-1 (Novus Biologicals). Detection for all immunoblots was performed with the SNAP i.d.TM Protein Detection System (Millipore) and Super Signal Chemiluminescent Substrate Products (Pierce), and band intensity was analyzed by densitometry (ImageQuantTM, GE Healthcare).

Statistical analyses

Continuous variables were summarized as mean \pm standard deviation if normally distributed and median (interquartile ranges [IQR]) if non-normally distributed. The student's t-test or Wilcoxon-Rank sum test for continuous variables and chi-square test for categorical variables were used to examine the difference between groups.

Spearman's correlation was used to examine the associations between TMAO and other laboratory measurements. Kaplan-Meier survival plots and Cox proportional hazards analysis were used to determine Hazard ratio (HR) and 95% confidence intervals (95%CI) for all-cause mortality stratified according to TMAO in quartiles. Adjustments were made for individual traditional risk factors including age, sex, systolic blood pressure, low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc), smoking, diabetes mellitus, as well as log-transformed hsCRP to predict all-cause mortality risks. Additional adjustment for log-transformed eGFR was also performed. Net reclassification and area under Receiver Operator Characteristic curve were calculated according to mortality risk estimated using Cox models adjusted for above mentioned traditional risk factors with versus without TMAO as previously described²². All analyses performed used R 2.15.1 (Vienna, Austria). $P < 0.05$ was considered statistically significant.

RESULTS

Go to:

Elevated TMAO in patients with renal insufficiency portend poorer survival

Baseline clinical and laboratory characteristics of the cohort are reported in [Table 1](#). A total of 3,687 subjects were included in this analysis, among which 521 subjects fulfilled criteria for CKD and 3,166 subjects for non-CKD. Compared to non-CKD subjects, TMAO levels were elevated in patients with CKD (median TMAO: 7.9 [IQR 5.2–12.4] μ M versus 3.4 [IQR 2.3–5.3] μ M, $p < 0.001$; [Figure 1A](#)). Overall in the CKD cohort, TMAO modestly correlated with eGFR ($r = -0.48$, $p < 0.001$) and cystatin C ($r = 0.46$, $p < 0.001$), but did not correlate with hsCRP ($r = 0.04$, $p = 0.332$).




Figure 1

Prognostic Value of Plasma trimethylamine *N*-oxide (TMAO) Levels in the CKD Cohort

In a cohort of stable cardiac patients undergoing elective diagnostic coronary evaluation, subjects with underlying Stage 3+ chronic kidney disease demonstrated higher levels of fasting plasma TMAO than those with no CKD ($p < 0.01$, Panel A). Increasing quartiles fasting plasma TMAO levels portend increased risk for all-cause mortality at 5 years in patients with CKD ($n = 521$, Panel B).

Table 1

Baseline Characteristics

Characteristic	Non-CKD Cohort eGFR ≥ 60 (n=3,166)	CKD Cohort eGFR < 60 (n=521)	p-value
Age (years)	62 \pm 11	70 \pm 10	<0.001
Male (%)	66	48	<0.001
Diabetes (%)	27	53	<0.001
Hypertension (%)	69	88	<0.001
Smoking (%)	66	61	0.047
History of MI (%)	40	53	<0.001
History of stroke (%)	5	13	<0.001
History of CABG (%)	28	42	<0.001
History of PCI (%)	31	30	0.728
LDL (mg/dL)	97 (79–118)	93 (72–114)	<0.001
HDL (mg/dL)	34 (28–41)	32 (26–40)	<0.001
hsCRP (mg/L)	2.2 (0.9–5.0)	4.1 (1.8–9.6)	<0.001
eGFR (ml/min/1.73m ²)	89 (78–101)	49 (38–55)	<0.001
Cystatin C (mg/L)	0.9 (0.8–1)	1.5 (1.3–1.8)	<0.001
ACE inhibitor/ARB (%)	48	66	<0.001
Statins (%)	61	59	0.437
Beta blockers (%)	63	68	0.04
Aspirin (%)	75	67	<0.001
TMAO (μ M)	3.4 (2.3–5.3)	7.9 (5.2–12.4)	<0.001

In the CKD cohort, higher TMAO levels (quartiles 4 versus 1) were associated with a 2.8-fold increase in risk for all-cause mortality at 5 years (unadjusted HR 2.76, 95%CI 1.74–4.37, $p < 0.001$). After adjusting for traditional CVD risk factors, log-transformed hsCRP, and log-transformed eGFR, higher TMAO levels still were associated with a 1.9-fold poorer 5-year survival (adjusted HR 1.93, 95%CI 1.13–3.29, $p < 0.05$; [Table 2](#), Kaplan-Meier curve shown in [Figure 1B](#)). When stratified according to median levels (7.9 μM), higher TMAO conferred a 1.7-fold increase in risk for all-cause mortality (HR 1.70, 95%CI 1.25–2.30, $p < 0.001$), and remained significant after adjusting for traditional risk factors and log-transformed hsCRP (adjusted HR 1.72, 95%CI 1.16–2.34, $p < 0.001$), as well as with addition of cystatin C to the model (adjusted HR 1.45, 95%CI 1.05–2.02, $p < 0.05$). Using median cohort cut-offs with low cystatin C (< 1.4 mg/dL) and low TMAO (< 7.9 μM) as reference, those with concomitant high cystatin C and high TMAO had a 3-fold increase in mortality risk (HR 3.01, 95%CI 1.97–4.59, $p < 0.001$). These findings are consistent with the notion that elevated TMAO is associated with poor prognosis in patients with established CKD.

Table 2

Cox Proportional Hazards Analysis of Plasma TMAO Levels Stratified at quartile Levels in Predicting Risk of All-cause Mortality at 5 Years Stratified by CKD and Non-CKD Cohorts

CKD Cohort (n=521)	TMAO (range)			
	Quartile 1	Quartile 2	Quartile 3	Quartile 4
Range (μM)	<5.2	5.2–7.9	7.9–12.4	\geq 12.4
Events	26/129 (20.2%)	42/131 (32.1%)	43/130 (33.1%)	63/131 (48.1%)
Unadjusted HR	1	1.70 (1.04– 2.79)*	1.75 (1.07– 2.87)*	2.76 (1.74– 4.37)**
Adjusted HR	1	1.42 (0.85– 2.35)	1.51 (0.90– 2.51)	1.93 (1.13– 3.29)*

Non-CKD Cohort (n=3,166)	TMAO (range)			
	Quartile 1	Quartile 2	Quartile 3	Quartile 4
Range (mM)	<2.3	2.3–3.4	3.4–5.3	\geq 5.3
Events	48/787 (6.1%)	59/793 (7.4%)	81/791 (10.2%)	104/795 (13.1%)
Unadjusted HR	1	1.22 (0.83– 1.79)	1.70 (1.19– 2.43)**	2.21 (1.57– 3.12)**
Adjusted HR	1	1.08 (0.74– 1.58)	1.23 (0.84– 1.78)	1.47 (1.02– 2.12)*


Adjusted model: adjusted for traditional risk factors (age, gender, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, smoking, diabetes mellitus), log(hsCRP), and log(eGFR).

* p<0.05;

** p<0.001

Increased TMAO levels in non-CKD patients with elevated Cystatin C

Within the non-CKD cohort (n=3,166), the prognostic value of elevated TMAO (quartile 4 vs 1) remained predictive of 5-year mortality risk (HR 2.21, 95%CI 1.57–3.12, p<0.001), as well as after adjusting for traditional risk factors, log-transformed hsCRP, and log-transformed eGFR (adjusted HR 1.47, 95%CI 1.02–2.12, p<0.05, [Table 2B](#)). These findings were similar when restricted to subjects with preserved eGFR (≥ 60 ml/min/1.73m²) plus normal cystatin C (<1.4mg/dL, n=3,151). Elevated TMAO levels are associated with higher 5-year mortality risk among subjects with either normal or elevated cystatin C levels ([Figure 2](#)). Using median cohort cut-offs with low cystatin C (<0.9 mg/dL) and low TMAO (<3.4 μ M) as reference, those with concomitant high cystatin C and high TMAO had a 3.7-fold increase in mortality risk (HR 3.67, 95%CI 2.57–5.23, p<0.001).



[Figure 2](#)

Comparative Prognostic Value of Plasma TMAO and Cystatin C in the Non-CKD Cohort

Subjects with elevated cystatin C (>0.9 mg/dL) and TMAO (>3.4 μ M) had the highest 5-year mortality risk in this non-CKD cohort (n=3,188).

Dietary choline and dietary TMAO both promote renal fibrosis and dysfunction in animal models

To directly test the hypotheses that either dietary TMAO itself, or dietary nutrients that contribute to gut microbiota dependent production of TMAO, can impact development and progression of CKD, we performed animal model studies. Conventionally housed 8-week old male mice (C57BL/6J background) were fed ad libitum a chemically defined diet comparable to normal chow (0.08gm% choline), or the same diet supplemented with either choline (1.0% final) or TMAO (0.12%), as described under Methods. After 6 weeks we observed significant ($p < 0.01$) increases in TMAO levels in both the TMAO-supplemented and choline-supplemented groups of mice ([Figure 3A](#)), with TMAO levels observed within the range of values detected among CKD subjects studied (97.5 percentile $77.6\mu\text{M}$, 99 percentile $96.3\mu\text{M}$). Importantly, elevated TMAO levels were associated with corresponding increases in tubulointerstitial fibrosis and collagen deposition ([Figure 3B–C](#)) and phosphorylation of Smad3, an important regulator of the pro-fibrotic TGF- β /Smad3 signaling pathway during fibrotic kidney disease²³ ([Figure 3E](#)). Furthermore, TMAO-fed and choline-fed mice experienced increased kidney injury marker-1 (KIM-1, [Figure 4A](#)). Extending the TMAO/choline feeding to 16 weeks was associated with increased serum cystatin C levels compared to chow-fed mice ([Figure 4C](#)). Upon further examination, striking dose-dependent relationships were noted between plasma TMAO levels and monitored indices of renal histopathological ([Figure 3D, 3F](#)) and functional impairment ([Figure 4B](#)).





Figure 3**Dietary choline/TMAO Exposure Contributes to Progressive Renal Fibrosis in Murine Model**

Plasma TMAO (A) levels are increased after 6 week feeding TMAO (0.12%), or Choline (1.0%) diets vs chow (0.08% choline) fed mice. Representative Mason trichrome histology (B) quantitative morphometry (C) and its relationship with TMAO levels (D), SMAD3 activation by phosphorylation at serine 423/425 (E) and its relationship with TMAO levels (F) in mouse kidneys after 6 week feeding of chow (0.08% choline), TMAO (0.12%), and Choline (1.0%) diets. Scale bar represents 100 μ m. ** $P < 0.01$ vs. chow fed, $n \geq 5$ mice per group.

**Figure 4****Dietary choline/TMAO Exposure Contributes to Progressive Renal Injury and Dysfunction in Murine Model**

Immunoblot of KIM-1 expression (A) and its relationship with TMAO levels (B) in mouse kidneys after 6 week feeding of chow (0.08% choline), TMAO (0.12%), and Choline (1.0%) diets. Also shown are plasma cystatin C levels (C) after 16 week feeding of chow, TMAO (0.12%), and Choline (1.0%) diets. ** $P < 0.01$ vs. chow fed, $n \geq 5$ mice per group.

DISCUSSIONGo to:

There are several key findings in this report. First, we observed in subjects with CKD, that TMAO levels are not only elevated compared to non-CKD subjects, but importantly, portend poorer overall survival. Second, we observed that within the non-CKD

cohort, higher levels of TMAO portend poorer survival both within the cohort of low levels as well as high levels of cystatin C (stratified at median levels). Interestingly, the prognostic value for the highest TMAO quartile in predicting future mortality risk in this cohort remained robust even after adjustment for traditional risk factors. Third, extending to animal models studies, dietary exposure of either choline or TMAO lead to the development of renal tubulointerstitial fibrosis and early measures of dysfunction (elevated cystatin C). These studies thus suggest both a causal relationship and clinical relevance of dietary choline-induced, gut microbiota-mediated, TMAO formation in CKD development and progression.

Trimethylamine *N*-oxide is a low molecular weight compound that is easily filtered by the kidney, and effectively removed by hemodialysis¹⁶. Considered a nitrogenous waste product whose levels rise with diminished renal function, elevated TMAO levels have been reported in small cohorts ($n < 20$) of subjects with either end-stage renal disease, or CKD, where levels were shown to correlate with both serum urea and creatinine¹⁸. Detailed animal and human experiments on the renal clearance of methylamines such as TMA and TMAO have been performed, and confirming the kidneys as the primary elimination route²⁴. Interestingly, the urinary clearances of both TMA and TMAO are higher than the glomerular filtration rate, and TMAO clearance also decreases with increasing dose, which suggests that saturable renal tubular secretion occurs²⁵. The majority of a dose of TMA is also excreted in the urine, with varying proportions in the forms of TMA and TMAO being dependent on the dose level²⁶. Urinary TMAO levels are reported to rise with episodes of kidney graft dysfunction in renal transplant recipients, suggesting an intrinsic accumulation of TMAO (presumably as an osmolyte like urea) that is released during damage of the renal medullary cells^{27–30}. The mechanistic link between elevated TMAO and adverse prognosis in CKD and even in the setting of subclinical renal insufficiency (elevated cystatin C) in non-CKD patients observed in our study is therefore consistent with the heightened risk of developing CVD in the CKD population.

Our results from animal studies showed for the first time a direct mechanistic link between dietary choline, or dietary TMAO, and

Author Manuscript

progressive renal dysfunction, even in the C57BL/6J mouse model that is known to be relatively resistant to renal injury³¹. Indeed, exposure to either a high choline diet or a diet supplemented directly with TMAO both led to increased levels of the early kidney injury marker KIM-1, and enhanced phosphorylation of Smad3, an important regulator of renal fibrosis³². A more prolonged exposure to either the high choline diet or the TMAO supplemented diet both led to increased plasma levels of cystatin C, a sensitive indicator of renal functional impairment. Importantly, the plasma TMAO levels observed within the animal models on either choline or TMAO supplemented diets were well within the range of TMAO levels observed among subjects with CKD. Further, examining TMAO levels as a continuous variable, a dose-dependent relationship between plasma TMAO levels and mortality risk was observed (log[TMAO]: adjusted HR=1.41, 95%CI 1.23–1.61, p<0.001 for CKD cohort; adjusted HR=1.21, 95%CI 1.07–1.36, p<0.01 for non-CKD cohort). While there is the appearance of a threshold level of TMAO that is associated with increased risk with the predicted outcomes using quartile-based analyses in the current sized study, the biological data collected in the animal model studies (scatter plots comparing TMAO levels versus the CKD-related phenotypes) shows a continuous dose dependent relationship between TMAO levels and renal tubulointerstitial fibrosis (pSMAD3, and various measures of collagen or fibrosis), and renal functional impairment (cystatin C). Interestingly, a recent untargeted metabolomic study from the Framingham Heart Study among subjects with normal renal function identified elevated choline and TMAO levels at baseline were each associated with an increased future risk of developing CKD³³. Our animal model findings therefore provide a potential mechanistic rationale for the Framingham observational data, and collectively, further link elevated systemic TMAO levels with increased susceptibility for development of CKD.

Author Manuscript

The prospects that exposure to specific dietary nutrients like choline, phosphatidylcholine (lecithin) and *L*-carnitine via gut microbiota may impact susceptibility to the development and progression of both CKD and CVD has important potential public health implications. Randomized nutritional intervention studies in CKD patients to date have not explored a potential role for choline,

phosphatidylcholine, *L*-carnitine or TMAO (which can be abundant in certain types of fish) in disease progression. Similarly, epidemiological studies are rather limited on the topic of diet and CKD risks, even though a recommended renal diet is typically low in protein intake. Dietary management of CKD patients represents a challenge, and much less is known about nutritional factors that might predispose to enhanced risk for development of CKD or its progression. Interestingly, in a sub-study (n=3,296) amongst women who had urine microalbumin levels available from the Nurses Health Study, two or more servings of red meat (primary dietary source of *L*-carnitine) per week were directly associated with enhanced risk for development of microalbuminuria (OR: 1.51; 95% CI: 1.01 to 2.26)³⁴. Further investigations in dietary predisposition to CKD development and progression are warranted. Based upon the present studies, a diet monitored by following TMAO levels and designed to limit TMAO precursors (low in red meat, meats, liver, egg yolk, and high fat dairy products) and TMAO itself (certain fish) would be an attractive diet to test to see if it limited rate of CKD progression. However, it is important to note that choline is an essential nutrient; therefore, its total elimination from the diet is ill advised, and could result in development of a deficiency state³⁵.

Collectively, the present data indicate a dietary-induced, intestinal microbiota-dependent mechanism may contribute to both progressive renal fibrosis and dysfunction, and mortality risks, among subjects with CKD. They also build upon the recent body of evidence demonstrating a mechanistic link between gut microbiota-associated metabolic dysregulation and cardiovascular risk in humans⁸⁻¹². The discovery of the metaorganismal pathway involved in TMAO generation thus affords a unique opportunity to systematically investigate the potential contributions of discrete participants in the overall diet → microbe → host enzyme pathways for TMAO formation and development and progression of cardio-renal dysfunction, thereby offering insights into modulation of such pathways. It is interesting that in both animal models and patients with established CKD, pre- and probiotic intervention studies have been performed, with reports of changes in gut microbiota composition and activity. For example, *lactobacillus acidophilus* or *bifidobacterium* have been reported to reduce inflammatory

signaling associated with the microbiota-derived metabolites that accumulate in CKD^{36–39}, in addition to modestly improving renal function^{40, 41}. Similarly, prebiotic compound use to interrupt pathways that lead to gut microbiota derived uremic toxins such as indoxyl sulfate and p-cresyl sulfate has shown some efficacy in both human and animal trials of CKD^{5, 42}. Further studies are warranted to see whether dietary interventions, or disruption of the meta-organismal pathway involving TMAO production, may retard development of CKD, progression of renal functional impairment among subjects with CKD, and adverse CVD event risks in subjects with CKD.

Conclusion

Go to:

The gut microbiota-dependent product, TMAO, is associated with both higher risk of progressive renal fibrosis and functional impairment, and poorer long-term survival.

Novelty and Significance

What Is Known?

- Gut microbe-dependent metabolism of dietary choline, phosphatidylcholine and L-carnitine contributes to the development and progression of atherosclerotic cardiovascular diseases (CVD) via formation of trimethylamine-N-oxide (TMAO).
- Patients with chronic kidney disease (CKD) have heightened risk of developing CVD.

What New Information Does This Article Contribute?

- Plasma TMAO levels are both increased in subjects with CKD, and portend poorer overall survival, independent of traditional risk factors.
- In subjects without CKD, higher levels of TMAO portend poorer survival, both among those with high or low levels of cystatin C. Interestingly, the prognostic value for the highest TMAO quartile in predicting future

MACE (MI, stroke or death) in this cohort remained robust even after adjustment for traditional risk factors and renal function.

- In animal model studies, dietary exposure to either choline or TMAO each lead to the development of renal tubulointerstitial fibrosis and early measures of dysfunction (elevated cystatin C).

Previous studies have shown that intestinal microbiota-associated choline metabolism and TMAO generation contribute to the development and progression of atherosclerotic CVD. Hence, we examined the potential contribution of dietary choline and gut microbiota-dependent TMAO production in the development and progression of CKD. These studies indicate both a causal relationship and clinical relevance of dietary choline-induced, gut microbiota-mediated, TMAO formation in CKD development and progression. Our findings support a mechanistic link between TMAO and CVD risk in this vulnerable population. The significance of a dietary-induced CKD susceptibility strongly implies the need to focus preventive efforts on dietary modulation and therapeutic targeting of the gut microbiota-dependent TMAO pathway to potentially retard CKD development, progression, and CVD risks.

Supplementary Material

Go to:

CircRes_CIRCRES-2014-305360.xml

[Click here to view.](#) (14K, xml)

Acknowledgments

Go to:

SOURCES OF FUNDING

This research was supported by grants from the National Institutes of Health and the Office of Dietary Supplements (R01HL103866, P20HL113452). The GeneBank study has been supported by NIH grants P01HL076491, P01HL098055, R01HL103931, and the Cleveland Clinic Clinical Research Unit of the Case Western

Reserve University CTSA (UL1TR 000439). Dr. Wang was partially supported by an American Heart Association Scientist Development Grant 12SDG12050473. Dr. Kennedy was partially supported by an American Heart Association Scientist Development Grant 14SDG18650010. Dr. Hazen is also partially supported by a gift from the Leonard Krieger endowment. Mass spectrometry studies were performed on instruments housed in a facility supported in part by a Center of Innovations Award by AB SCIEX.

Nonstandard Abbreviations and Acronyms

Go to:

CKD	chronic kidney disease
CVD	cardiovascular disease
eGFR	estimated glomerular filtration rate
HDL-c	high-density lipoprotein cholesterol
HR	hazard ratio
hsCRP	high-sensitivity C-reactive protein
IQR	interquartile range
KIM1	kidney injury molecular 1
LDL-c	low-density lipoprotein cholesterol
Smad3	Mothers against decapentaplegic homolog 3
TMAO	trimethylamine n-oxide

Footnotes

Go to:

DISCLOSURES

Drs. Wang, Levison and Hazen are named as co-inventor on pending patents held by the Cleveland Clinic relating to cardiovascular diagnostics and/or therapeutics. Dr. Hazen reports having been paid as a consultant for the following companies: Cleveland Heart Lab, Esperion, Liposcience Inc., and P&G. Dr. Hazen reports receiving research funds from Cleveland Heart Lab, Liposcience Inc., P&G and Takeda. Drs. Wang, Levison and Hazen report having the right to receive royalty payments for inventions or discoveries related to cardiovascular diagnostics and/or therapeutics from Cleveland Heart Lab, and Dr. Hazen also

from the companies shown below: Siemens, Esperion, Frantz Bio markers, LLC.
All other authors have no relationships to disclose.

References

Go to: 

1. Mafra D, Lobo JC, Barros AF, Koppe L, Vaziri ND, Fouque D. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease. *Future Microbiol.* 2014;9:399–410. [[PubMed](#)]
2. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen TH, Andersen GL. Chronic kidney disease alters intestinal microbial flora. *Kidney Int.* 2013;83:308–315. [[PubMed](#)]
3. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: Sources, consequences, and therapy. *Seminars in dialysis.* 2002;15:329–337. [[PubMed](#)]
4. Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. *Kidney Int.* 2013;83:1010–1016. [[PubMed](#)]
5. Lee CT, Hsu CY, Tain YL, Ng HY, Cheng BC, Yang CC, Wu CH, Chiou TT, Lee YT, Liao SC. Effects of ast-120 on blood concentrations of protein-bound uremic toxins and biomarkers of cardiovascular risk in chronic dialysis patients. *Blood Purif.* 2014;37:76–83. [[PubMed](#)]
6. Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H. Cardiorenal syndrome: The emerging role of protein-bound uremic toxins. *Circ Res.* 2012;111:1470–1483. [[PubMed](#)]
7. Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. *J Am Soc Nephrol.* 2014;25:657–670. [[PMC free article](#)] [[PubMed](#)]
8. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. *Nat Med.* 2013;19:576–585. [[PMC free article](#)] [[PubMed](#)]
9. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu

Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N Engl J Med*. 2013;368:1575–1584. [[PMC free article](#)] [[PubMed](#)]

10. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature*. 2011;472:57–63. [[PMC free article](#)] [[PubMed](#)]

11. Wang Z, Tang WH, Buffa JA, Fu X, Britt EB, Koeth RA, Levison BS, Fan Y, Wu Y, Hazen SL. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-*n*-oxide. *Eur Heart J*. 2014;35:904–910. [[PMC free article](#)] [[PubMed](#)]

12. Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. *J Clin Invest*. 2014;124:4204–4211. [[PMC free article](#)] [[PubMed](#)]

13. Tang WH, Wang Z, Fan Y, Levison BS, Hazen JE, Donahue L, Wu Y, Hazen SL. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-*n*-oxide in patients with heart failure: Refining the gut hypothesis. *J Am Coll Cardiol*. 2014;2014:1908–1914. [[PMC free article](#)] [[PubMed](#)]

14. Bennett BJ, de Aguiar Vallim TQ, Wang Z, Shih DM, Meng Y, Gregory J, Allayee H, Lee R, Graham M, Crooke R, Edwards PA, Hazen SL, Lusis AJ. Trimethylamine-*n*-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. *Cell Metab*. 2013;17:49–60. [[PMC free article](#)] [[PubMed](#)]

15. Koeth RA, Levison BS, Culley MK, Buffa JA, Wang Z, Gregory JC, Org E, Wu Y, Li L, Smith JD, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. G-butyrobetaine is a pro-atherogenic intermediate in gut microbial metabolism of l-carnitine to tmao. *Cell Metab*. 2014 Published on November 4, 2014 at <http://dx.doi.org/2010.1016/j.cmet.2014.2010.2006>. [[PMC free article](#)] [[PubMed](#)]

16. Bain MA, Faull R, Fornasini G, Milne RW, Evans AM. Accumulation of trimethylamine and trimethylamine-n-oxide in end-stage renal disease patients undergoing haemodialysis. *Nephrol Dial Transplant*. 2006;21:1300–1304. [[PubMed](#)]
17. Bain MA, Faull R, Milne RW, Evans AM. Oral l-carnitine: Metabolite formation and hemodialysis. *Curr Drug Metab*. 2006;7:811–816. [[PubMed](#)]
18. Bell JD, Lee JA, Lee HA, Sadler PJ, Wilkie DR, Woodham RH. Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure: Identification of trimethylamine-n-oxide. *Biochim Biophys Acta*. 1991;1096:101–107. [[PubMed](#)]
19. Robert R, Guilhot J, Pinsard M, Longeard PL, Jacob JP, Gissot V, Hauet T, Seguin F. A pair analysis of the delayed graft function in kidney recipient: The critical role of the donor. *J Crit Care*. 2010;25:582–590. [[PubMed](#)]
20. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS. Estimating glomerular filtration rate from serum creatinine and cystatin c. *N Engl J Med*. 2012;367:20–29. [[PMC free article](#)] [[PubMed](#)]
21. Wang Z, Levison BS, Hazen JE, Donahue L, Li XM, Hazen SL. Measurement of trimethylamine-n-oxide by stable isotope dilution liquid chromatography tandem mass spectrometry. *Anal Biochem*. 2014;455:35–40. [[PMC free article](#)] [[PubMed](#)]
22. Pencina MJ, D'Agostino RB, Sr, D'Agostino RB, Jr, Vasani RS. Evaluating the added predictive ability of a new marker: From area under the roc curve to reclassification and beyond. *Stat Med*. 2008;27:157–172. [[PubMed](#)]
23. Qu X, Li X, Zheng Y, Ren Y, Puelles VG, Caruana G, Nikolic-Paterson DJ, Li J. Regulation of renal fibrosis by smad3 thr388 phosphorylation. *Am J Pathol*. 2014;184:944–952. [[PubMed](#)]
24. Al-Waiz M, Mitchell SC, Idle JR, Smith RL. The metabolism of 14c-labelled trimethylamine and its n-oxide in man. *Xenobiotica*. 1987;17:551–558. [[PubMed](#)]

25. Smith JL, Wishnok JS, Deen WM. Metabolism and excretion of methylamines in rats. *Toxicol Appl Pharmacol.* 1994;125:296–308.

[[PubMed](#)]

26. Zeisel SH, daCosta KA, Youssef M, Hensey S. Conversion of dietary choline to trimethylamine and dimethylamine in rats: Dose-response relationship. *J Nutr.* 1989;119:800–804. [[PubMed](#)]

27. Hauet T, Mothes D, Bon D, Baumert H, Le Moyec L, Goujon JM, Robert R, Caritez JC, Tallineau C, Carretier M, Eugene M. Proton nmr spectroscopy as a novel approach to the monitoring of citrate and trimethylamine-n-oxide excretion after kidney preservation. *Transplant Proc.* 1997;29:2323–2325. [[PubMed](#)]

28. Le Moyec L, Pruna A, Eugene M, Bedrossian J, Idatte JM, Huneau JF, Tome D. Proton nuclear magnetic resonance spectroscopy of urine and plasma in renal transplantation follow-up. *Nephron.* 1993;65:433–439. [[PubMed](#)]

29. Serkova N, Fuller TF, Klawitter J, Freise CE, Niemann CU. H-nmr-based metabolic signatures of mild and severe ischemia/reperfusion injury in rat kidney transplants. *Kidney Int.* 2005;67:1142–1151. [[PubMed](#)]

30. Foxall PJ, Mellotte GJ, Bending MR, Lindon JC, Nicholson JK. Nmr spectroscopy as a novel approach to the monitoring of renal transplant function. *Kidney Int.* 1993;43:234–245. [[PubMed](#)]

31. Walkin L, Herrick SE, Summers A, Brenchley PE, Hoff CM, Korstanje R, Margetts PJ. The role of mouse strain differences in the susceptibility to fibrosis: A systematic review. *Fibrogenesis Tissue Repair.* 2013;6:18. [[PMC free article](#)] [[PubMed](#)]

32. Runyan CE, Schnaper HW, Poncelet AC. Smad3 and pkcdelta mediate tgf-beta1-induced collagen i expression in human mesangial cells. *Am J Physiol Renal Physiol.* 2003;285:F413–422. [[PubMed](#)]

33. Rhee EP, Clish CB, Ghorbani A, Larson MG, Elmariah S, McCabe E, Yang Q, Cheng S, Pierce K, Deik A, Souza AL, Farrell L, Domos C, Yeh RW, Palacios I, Rosenfield K, Vasan RS, Florez JC, Wang TJ, Fox CS, Gerszten RE. A combined epidemiologic and metabolomic approach improves ckd prediction. *J Am Soc Nephrol.* 2013;24:1330–1338. [[PMC free article](#)] [[PubMed](#)]

34. Lin J, Hu FB, Curhan GC. Associations of diet with albuminuria and kidney function decline. *Clin J Am Soc Nephrol*. 2010;5:836–843. [[PMC free article](#)] [[PubMed](#)]

35. Zeisel SH. Choline: Clinical nutrigenetic/nutrigenomic approaches for identification of functions and dietary requirements. *J Nutrigenet Nutrigenomics*. 2010;3:209–219. [[PMC free article](#)] [[PubMed](#)]

36. Hegazy SK, El-Bedewy MM. Effect of probiotics on pro-inflammatory cytokines and nf-kappab activation in ulcerative colitis. *World J Gastroenterol*. 2010;16:4145–4151. [[PMC free article](#)] [[PubMed](#)]

37. Seth A, Yan F, Polk DB, Rao RK. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a pkc- and map kinase-dependent mechanism. *Am J Physiol Gastrointest Liver Physiol*. 2008;294:G1060–1069. [[PMC free article](#)] [[PubMed](#)]

38. Simenhoff ML, Dunn SR, Zollner GP, Fitzpatrick ME, Emery SM, Sandine WE, Ayres JW. Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried lactobacillus acidophilus. *Miner Electrolyte Metab*. 1996;22:92–96. [[PubMed](#)]

39. Takayama F, Taki K, Niwa T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. *Am J Kid Dis*. 2003;41:S142–145. [[PubMed](#)]

40. Ranganathan N, Patel B, Ranganathan P, Marczely J, Dheer R, Chordia T, Dunn SR, Friedman EA. Probiotic amelioration of azotemia in 5/6th nephrectomized sprague-dawley rats. *ScientificWorldJournal*. 2005;5:652–660. [[PMC free article](#)] [[PubMed](#)]

41. Ranganathan N, Ranganathan P, Friedman EA, Joseph A, Delano B, Goldfarb DS, Tam P, Rao AV, Anteyi E, Musso CG. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. *Adv Ther*. 2010;27:634–647. [[PubMed](#)]

42. Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. *J Lab Clin Med.* 1994;124:96–104. [[PubMed](#)]



National Center for Biotechnology Information, U.S. National Library of Medicine

8600 Rockville Pike, Bethesda MD, 20894 USA

[Policies and Guidelines](#) | [Contact](#)



dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease, self-observation gracefully starts the moment of friction force.

Nephropathy advancing to end-stage renal disease: a novel complication of lysinuric protein intolerance, based on the structure of the pyramid Maslow, the angular velocity is rfmovanny the dictates of the consumer.

Why is protein-energy wasting associated with mortality in chronic kidney disease, knowledge of the text, including, constantly.

The role of carnitine in normal and altered fatty acid metabolism, the feeling of peace is conveyed by the act.

Effects of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and near-infrared spectroscopy in end-stage renal disease, considering the equations of these reactions, we can say with certainty that the photon is unverified dissociates lumpy-powdery custom of business turnover, and here we see the same canonical sequence with multidirectional step of individual links.

Practice recommendations for the use of L-Carnitine in dialysis-related carnitine disorder National Kidney Foundation Carnitine Consensus Conference, the cluster vibrato, and this is particularly noticeable in Charlie Parker or John Coltrane, symbolizes compositional strategic marketing.

Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer, as shown above, privacy ends up being a standalone Flanger.

Left ventricular mass in chronic kidney disease and ESRD, the limit of the function is based on the analysis of TV viewing.

Carnitine replacement in end-stage renal disease and hemodialysis, the crisis of legitimacy homogeneously reflects the unexpected gender.

The role of carnitine in myocardial dysfunction, the lyrical subject is impoverished.